Scientists probe Inflammation's role in protein metabolism

NCT ID NCT06721910

Completed Knowledge-focused Sponsor: University Hospital, Basel, Switzerland Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at whether interleukin-6 (a protein involved in inflammation) changes how glucagon (a hormone) lowers amino acid levels in the blood. Twenty-six healthy volunteers received either a drug that blocks interleukin-6 or a placebo, then had their amino acid and hormone levels measured. The goal was to better understand how these signals control protein balance in the body.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Tocilizumab
What this could lead to: If successful, this could help explain how inflammation affects protein metabolism, potentially guiding future treatments for conditions like diabetes or muscle wasting.
What could go wrong: This is a small, early-stage study in healthy people, not patients. Results may not apply to real diseases, and the intervention (tocilizumab) has known risks like infection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AMINO ACID CHANGE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AMINO ACID CHANGE GLUCAGON RESISTANCE HEALTHY

Contacts and locations

Show contact details

Locations

University Hospital Basel

Basel, 4031, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.